The State of GLP-1 and Incretin Research in 2026

Few areas of medicine have moved as fast as incretin pharmacology. What began in the 1980s and 1990s as an effort to exploit gut hormones for better blood-sugar control in type 2 diabetes has become, by 2026, one of the most active and consequential fields in all of metabolic medicine. The same hormone systems now anchor approved treatments for obesity, cardiovascular disease, obstructive sleep apnea, chronic kidney disease and metabolic liver disease.

The umbrella term most people use is 'GLP-1', after glucagon-like peptide-1. But the science has broadened well past a single hormone. The frontier now includes drugs that engage two or even three receptors at once: GLP-1, GIP (glucose-dependent insulinotropic polypeptide) and glucagon. Each addition changes the metabolic profile, and each is being tested in its own wave of large clinical trials.

This article is an editorial roundup of where that evidence actually stands. It distinguishes what regulators have approved from what is still investigational, separates human trial data from earlier-stage or animal work, and addresses the honest and often uncomfortable gap between prescription medicines and the unapproved 'research peptide' market that has grown up around them. It is educational only and is not medical advice.

When you eat, the gut releases hormones called incretins that prime the pancreas to respond to the incoming glucose. This 'incretin effect' is powerful: in healthy people it accounts for roughly half to two-thirds of the insulin released after a meal. In type 2 diabetes that response is blunted, often falling to a fraction of normal, which helped motivate the search for drugs that could restore it.

GLP-1 and GIP are the two principal incretins. Both bind class B G-protein-coupled receptors and signal mainly through the Gs-cAMP pathway, and both stimulate insulin release in a glucose-dependent way, which limits the risk of driving blood sugar too low. But they are not interchangeable. Reviews of incretin physiology note that GLP-1 tends to suppress glucagon when blood sugar is high, slows gastric emptying and reduces appetite by acting on satiety centers in the brain, while GIP has more nuanced effects, including a role in fat storage and glucagon regulation that differs from GLP-1.

Glucagon, the third player in the newest drugs, is often thought of only as the hormone that raises blood sugar. But it also increases energy expenditure and influences liver fat metabolism. Adding controlled glucagon-receptor activity to GLP-1 and GIP activity is the rationale behind triple agonists: the goal is greater fat loss and metabolic benefit while the GLP-1 component offsets glucagon's tendency to raise glucose. Native incretin hormones break down within minutes, so modern drugs are engineered, often with fatty-acid chains or as small molecules, to last long enough for weekly or daily dosing.

Semaglutide is the most thoroughly studied GLP-1 receptor agonist and the reference point against which newer drugs are measured. Marketed under different brand names for diabetes and for weight management, it began as a glucose-lowering therapy and has since accumulated one of the broadest evidence bases in the field.

Its most influential trial for a general audience was SELECT, which studied people with established cardiovascular disease and overweight or obesity but without diabetes. Semaglutide reduced major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, by about 20 percent compared with placebo (hazard ratio around 0.80). That result led United States regulators in March 2024 to approve semaglutide to reduce cardiovascular risk in this population, a milestone because the benefit was framed around heart outcomes rather than weight or glucose alone. Analyses published in 2025 estimated that millions of US adults could meet the trial's eligibility criteria.

The label has continued to widen. In early 2025 semaglutide gained a US indication, based on the FLOW trial, to slow kidney disease progression and reduce related death in adults who have both type 2 diabetes and chronic kidney disease. In August 2025 it became the first GLP-1 drug approved in the US for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis, after a trial in which a substantially higher proportion of treated patients achieved resolution of the liver inflammation than on placebo. Importantly, each of these approvals applies to a specific population; the evidence does not automatically extend to everyone who takes the drug for other reasons.

Tirzepatide was the first approved 'twincretin', a single molecule that activates both the GIP and GLP-1 receptors. Combining the two mechanisms produced larger effects on glucose and weight than GLP-1 alone in head-to-head testing, and its approvals have followed a similar expanding arc to semaglutide.

In its diabetes program (SURPASS) tirzepatide delivered strong reductions in HbA1c and supported its 2022 US approval for type 2 diabetes. Its obesity program (SURMOUNT) supported a separate 2023 approval for chronic weight management. In SURMOUNT-1, adults with obesity but without diabetes lost on average roughly 22 percent of body weight at the highest dose over 72 weeks, versus about 2 percent on placebo, among the largest effects reported for a single agent at that time. A later head-to-head trial, SURMOUNT-5, compared tirzepatide directly against semaglutide and reported greater average weight loss with tirzepatide, on the order of 20 percent versus roughly 14 percent.

Tirzepatide's reach has also grown. In December 2024 it became the first drug approved in the US to treat moderate to severe obstructive sleep apnea in adults with obesity, an indication built on trials showing reduced breathing disruption alongside weight loss. As with semaglutide, cardiovascular outcome testing has been a major focus, and the two drugs together have reframed incretin therapy as cardiometabolic medicine rather than narrow glucose control.

Retatrutide is the most closely watched of the next-generation agents. It activates three receptors at once, GLP-1, GIP and glucagon, and in 2026 it is investigational: it has not been approved by the FDA, the EMA or other major regulators, and it should be understood as an experimental compound still in Phase 3 testing.

That testing, the TRIUMPH and TRANSCEND programs, has generated striking numbers. In the pivotal TRIUMPH-1 obesity trial of more than 2,000 participants, the studied doses met their primary and key secondary endpoints, and people on the highest dose lost up to roughly 30 percent of body weight over about two years, among the largest reductions reported for any pharmacologic agent. A companion trial in adults with type 2 diabetes reported meaningful HbA1c and weight reductions, and investigators noted that weight loss had not clearly plateaued by the end of some studies. Additional Phase 3 readouts across obesity, diabetes, sleep apnea, metabolic liver disease and cardiovascular outcomes are expected to continue reporting through 2026 and beyond.

Enthusiasm should be tempered with the usual cautions for an unapproved drug. Adding glucagon activity raises questions that longer and larger trials are designed to answer, including effects on heart rate, blood pressure and glucose in different populations. Topline efficacy numbers from press releases and conference presentations are not the same as a complete, peer-reviewed safety record or a regulatory approval. Until those exist, retatrutide's ultimate place in therapy remains genuinely uncertain.

Most incretin drugs to date have required injection, which limits access and appeal for some people. A major theme of 2025 and 2026 research is the shift toward oral dosing, through two different chemical strategies.

The first is orforglipron, a small-molecule GLP-1 receptor agonist that, unlike peptide drugs, does not require special formulation to survive digestion. In the Phase 3 ATTAIN-1 obesity trial of more than 3,000 participants, orforglipron produced average weight loss of roughly 11 percent at 72 weeks at its highest dose, with a majority of high-dose participants losing at least 10 percent of body weight and with improvements in cardiometabolic markers. Its developer has moved toward regulatory submissions, positioning it as a potential first oral GLP-1 specifically for obesity, though its average effect trails the strongest injectables.

The second strategy is higher-dose oral semaglutide. Trials of a 25 mg oral formulation reported average weight loss in the mid-teens percent range over roughly a year, closing some of the historical gap between oral and injectable delivery. Head-to-head diabetes trials have also compared these oral agents against one another. The oral wave matters less because any single pill is dramatically better than injectables and more because convenience, adherence and scale could broaden who realistically uses these therapies, if cost and access follow.

The explosion of interest in GLP-1 science has a shadow. Alongside approved, quality-controlled prescription products, a large grey market has grown up selling semaglutide, tirzepatide and even copies of still-investigational compounds like retatrutide, frequently labeled 'for research use only' or 'not for human consumption'. That labeling is often a way to sidestep the rules that govern actual medicines, not a reflection of how the products are marketed or used.

The distinction is not a technicality. Approved medicines pass through regulatory review of safety, effectiveness and manufacturing quality, and are made under controlled conditions with verified identity, purity and sterility. Regulators including the FDA have publicly documented the opposite in parts of the unapproved market: counterfeit and compounded products with incorrect or even zero active ingredient, dangerous dosing errors, unapproved chemical salt forms, contamination and sterility concerns, temperature-abused shipments, and adverse events serious enough to require hospitalization. Independent testing of grey-market vials has repeatedly found contents that do not match the label.

For an educational hub, the responsible framing is straightforward. Prescription incretin drugs are powerful medicines with real risks as well as benefits, and they belong in a supervised clinical relationship, not a mail-order vial of unknown provenance. This article discusses prescription products to explain the science, not to promote their use, and it deliberately provides no dosing, protocols, sourcing or preparation guidance. Anyone weighing these therapies should do so with a qualified clinician using approved products.

Three trajectories define incretin research going into the second half of the 2020s. The first is more receptors and better tuning: after single, dual and now triple agonists, work continues on fine-tuning the balance between GLP-1, GIP, glucagon and other targets such as amylin, aiming for greater effect with better tolerability. The second is indication expansion beyond weight and glucose. Cardiovascular, kidney and liver outcome trials have already turned these drugs into cardiometabolic therapies, and researchers are actively studying whether benefits extend to areas such as sleep apnea, and, more speculatively and with far less mature evidence, to conditions like addiction and neurodegeneration.

The third is access and delivery: oral agents, potential future dosing convenience, biosimilar and generic competition as patents age, and the health-economics question of who can actually afford long-term therapy. Each of these will be shaped by data that does not yet exist, which is the central honest caveat of any 2026 snapshot.

It is worth restating what kind of evidence supports each claim. The strongest results here, cardiovascular risk reduction, large weight loss, kidney and liver benefits, come from randomized controlled trials in defined human populations. Much mechanistic detail, and many proposed 'off-label' or longevity-style uses circulating online, rest on shorter studies, animal models, in-vitro work or extrapolation. Distinguishing those tiers is the difference between an informed reader and a marketed one. The incretin story is genuinely one of the most important in modern medicine; it is also still being written.